Literature DB >> 8558845

Comparison of P53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects.

J A Vet1, P P Bringuier, H E Schaafsma, J A Witjes, F M Debruyne, J A Schalken.   

Abstract

BACKGROUND: Alterations of the tumor suppressor gene p53 are known to occur in bladder cancer. Although p53 overexpression is associated with mutation of the p53 gene, a substantial discrepancy between molecular genetic alteration in p53 and overexpression of the protein has been found. EXPERIMENTAL
DESIGN: Tumor specimens of 39 bladder cancer patients were immunohistochemically analyzed for p53 overexpression, and the results were compared with the presence of a mutation as assessed by single strand conformation polymorphism (SSCP) and direct sequencing. Both clinical and biologic aspects were studied.
RESULTS: A significant correlation between p53 overexpression and poor survival in the whole group studied was found (p < 0.01). No association between p53 overexpression and decreased survival was found for invasive tumors in contrast with other studies. Differences in treatment of the patients and different Ab and scoring systems used might explain these differences. In our study, the Kaplar-Meier curves showed the same result for p53 overexpression and p53 mutation when the whole group and the invasive tumors were studied. However, in the group of superficial tumors, which was unfortunately too small for statistical analysis, we found p53 overexpression in three tumors, and no p53 mutations were found. A good concordance between p53 mutation and p53 overexpression was found (p < 0.02). However, two out of eight tumors with an SSCP-proven p53 mutation showed no p53 immunoreactivity, probably as a result of loss of the nuclear localization signal. Twenty three percent (7/31) of the tumors showed p53 overexpression without any sign of a mutation.
CONCLUSIONS: Our results indicate that, despite good concordance between p53 mutation and p53 overexpression, there is no direct casual relationship between mutation and protein accumulation. Apparently, other events than mutation can trigger p53 stability.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8558845

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  10 in total

1.  A better surgical resectability of WHO grade II gliomas is independent of favorable molecular markers.

Authors:  Dominik Cordier; Catherine Gozé; Sabine Schädelin; Valérie Rigau; Luigi Mariani; Hugues Duffau
Journal:  J Neurooncol       Date:  2014-09-28       Impact factor: 4.130

2.  1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth.

Authors:  Catherine Gozé; Charlotte Bezzina; Eric Gozé; Valérie Rigau; Thierry Maudelonde; Luc Bauchet; Hugues Duffau
Journal:  J Neurooncol       Date:  2012-03-06       Impact factor: 4.130

Review 3.  Molecular pathways in bladder cancer.

Authors:  Stephen G Williams; John P Stein
Journal:  Urol Res       Date:  2004-11-13

4.  Apoptosis and proliferation: correlation with p53 in astrocytic tumours.

Authors:  Chitra Sarkar; Asis Kumar Karak; Neera Nath; Mehar Chand Sharma; Ashok Kumar Mahapatra; Parthoprasad Chattopadhyay; Subrata Sinha
Journal:  J Neurooncol       Date:  2005-06       Impact factor: 4.130

5.  Detection of p53 gene mutations by nonisotopic RNase cleavage assay as a predictor of poor prognosis in colorectal cancers.

Authors:  Masatoshi Haseba; Shigekazu Hidaka; Takashi Tsuji; Hiroshi Yano; Hideaki Komatsu; Terumitu Sawai; Toru Yasutake; Tohru Nakagoe; Yutaka Tagawa; Hiroyoshi Ayabe
Journal:  Dig Dis Sci       Date:  2003-10       Impact factor: 3.199

6.  Frequent and heterogeneous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma.

Authors:  S Clasen; W A Schulz; C D Gerharz; M O Grimm; F Christoph; B J Schmitz-Dräger
Journal:  Br J Cancer       Date:  1998-02       Impact factor: 7.640

7.  G1 checkpoint protein and p53 abnormalities occur in most invasive transitional cell carcinomas of the urinary bladder.

Authors:  G A Niehans; R A Kratzke; M K Froberg; D M Aeppli; P L Nguyen; J Geradts
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

8.  Specific-mutational patterns of p53 gene in bladder transitional cell carcinoma among a group of Iraqi patients exposed to war environmental hazards.

Authors:  Thekra A Al-Kashwan; Massoud Houshmand; Asaad Al-Janabi; Alice K Melconian; Dhafir Al-Abbasi; Muhammad N Al-Musawi; Maryam Rostami; Akeel A Yasseen
Journal:  BMC Res Notes       Date:  2012-08-28

9.  Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis.

Authors:  R Abdel-Fattah; C Challen; T R Griffiths; M C Robinson; D E Neal; J Lunec
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

10.  A population-based study of immunohistochemical detection of p53 alteration in bladder cancer.

Authors:  K T Kelsey; T Hirao; A Schned; S Hirao; T Devi-Ashok; H H Nelson; A Andrew; M R Karagas
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.